Curium, a radiopharmaceuticals maker backed by private equity firm CapVest, has agreed to acquire rival Lantheus in a deal that could be worth up to $8 billion, according to a Reuters report. The acquisition is the latest in a string of big-ticket deals in the fast-growing field of radiopharmaceuticals, which pairs radioactive compounds with medicines to diagnose and treat diseases like cancer.
Under the terms, Lantheus shareholders will receive $102.50 per share in cash, plus up to an additional $12 per share if the company hits certain sales targets by 2030. That structure gives Lantheus investors a guaranteed payout now, with the potential for more if the business performs well over the next several years.
Why radiopharmaceuticals are hot
Radiopharmaceuticals work by attaching a radioactive isotope to a molecule that targets specific cells, such as cancer cells. The radiation can then destroy those cells or make them visible on imaging scans. This targeted approach can be more precise than traditional treatments, potentially reducing damage to healthy tissue.
Large drugmakers have been eager to get a foothold in this space. The Reuters report noted several recent tie-ups: Bristol Myers Squibb’s roughly $4.1 billion purchase of RayzeBio, AstraZeneca’s Fusion Pharmaceuticals deal worth up to about $2.4 billion, and Eli Lilly’s roughly $1.4 billion acquisition of Point Biopharma. These deals reflect a broader industry bet that radiopharmaceuticals will become a major treatment modality for cancer and other diseases.
For Curium, buying Lantheus gives it a larger portfolio of products and a bigger pipeline, as well as access to Lantheus’s commercial infrastructure. The combined company would be better positioned to compete with the pharmaceutical giants that are also investing heavily in this area.
What the deal means for Lantheus shareholders
For Lantheus investors, the offer of $102.50 per share in cash represents a fixed, immediate value. The additional $12 per share in potential milestone payments is contingent on the company meeting sales targets by 2030. That means the total value could reach $114.50 per share if those targets are met, but there’s no guarantee they will be.
Deals with earn-out provisions are common in the pharmaceutical industry, especially when the buyer wants to incentivize the seller’s team to keep growing the business after the acquisition. For shareholders, the cash component provides certainty, while the earn-out adds upside if the company performs well.
It’s worth noting that the deal is subject to regulatory approvals and other customary closing conditions. Until the deal closes, Lantheus shares will likely trade at a discount to the offer price, reflecting the risk that the transaction might not go through or that the timing could be delayed.
What it means for everyday investors
For investors who own Lantheus shares, the deal offers a clear exit at a set price. If you’re a long-term holder, you’ll need to decide whether to accept the cash now or hold out for the potential milestone payments. But remember, this is not personalized financial advice—it’s just an explanation of how the deal works.
For investors in the broader healthcare sector, this acquisition is a signal that radiopharmaceuticals are becoming a mainstream investment theme. As more large companies enter the space, smaller players could become acquisition targets, which might boost their stock prices. However, investing in biotech and pharma carries significant risk, and not every deal will succeed.
The deal also highlights the ongoing consolidation in the healthcare industry. Private equity firms like CapVest are increasingly active in buying and merging companies to create larger, more efficient players. This trend could continue, especially in niche areas like radiopharmaceuticals where scale matters for research and development.
Looking ahead
Investors will be watching for regulatory approval and any potential antitrust concerns. The deal is expected to close in the coming months, though no specific timeline was given. If approved, it will create one of the largest independent radiopharmaceutical companies, with a broad portfolio and a strong pipeline.
For now, the market’s reaction will depend on how investors view the price and the likelihood of the milestone payments. The cash component provides a floor, but the earn-out adds uncertainty. As with any acquisition, there’s also the risk that the integration of the two companies could be more difficult than expected, which could affect the combined company’s performance.
In the meantime, the deal is a reminder that healthcare innovation often comes with big price tags. For investors, it’s a chance to see how the industry is evolving and where the next growth areas might be.
